Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$43.95

-0.03 (-0.07%)

, FATE

Fate Therapeutics

$19.51

-0.2 (-1.01%)

05:24
06/27/19
06/27
05:24
06/27/19
05:24

Piper keeps Crispr, Fate as top picks for 2019, adds Arvinas

Piper Jaffray analyst Edward Tenthoff revisited his top picks Biotechnology picks into the second half of 2019, including Crispr Therapeutics (CRSP) and Fate Therapeutics (FATE), and he added Arvinas (ARVN). ). For Crispr, he anticipates first-in-man CTX001 data in transfusion-dependent beta thalassemia patients likely in December to serve as a "major driver." For Fate, the analyst anticipates first-in-man iPSC derived NK cell data on FT500, as well as Phase I study start of FT516 and an investigational new drug filing for FT596 all this year. And for Arvinas, the FDA has cleared the IND for estrogen degrader ARVN-471 and Arvinas will initiate a Phase I study in Q3, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Crispr with a $100 price target, an Overweight rating on Fate with a $30 price target, and an Overweight rating on Arvinas with a $32 price target.

CRSP

Crispr Therapeutics

$43.95

-0.03 (-0.07%)

FATE

Fate Therapeutics

$19.51

-0.2 (-1.01%)

ARVN

Arvinas

$23.38

0.93 (4.14%)

  • 09

    Sep

CRSP Crispr Therapeutics
$43.95

-0.03 (-0.07%)

06/10/19
ROTH
06/10/19
INITIATION
Target $50
ROTH
Buy
Crispr Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler started Crispr Therapeutics with a Buy rating and $50 price target. The analyst notes that Crispr's most advanced program is for genetically-defined diseases of transfusion-dependent beta-thalassemia and severe sickle cell disease. These are hemoglobinopathies with high unmet need, and the opportunity could be significant for a potentially curative therapy, he contends.
06/07/19
WELS
06/07/19
NO CHANGE
Target $65
WELS
Outperform
Crispr's expanded Vertex deal validates gene editing platform, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated an Outperform rating and $65 price target on Crispr Therapeutics (CRSP) after the company announced an expanded alliance with Vertex (VRTX) to develop gene editing medicines to treat Duchenne muscular dystrophy and myotonic dystrophy type 1. In a research note to investors, Birchenough says he views the expanded collaboration as validating Crispr's CRISPR/CAS9 gene editing platform, providing a meaningful non-dilutive source of capital and future longer-term funding and with significant upside potential in DMD and DM1.
06/07/19
PIPR
06/07/19
NO CHANGE
Target $100
PIPR
Overweight
Crispr Therapeutics price target raised to $100 from $75 at Piper Jaffray
Crispr Therapeutics (CRSP) and Vertex (VRTX) expanded their alliance to develop gene editing medicines to treat Duchenne muscular dystrophy and myotonic dystrophy type 1 with Crispr receiving $175M in cash up front and being eligible for $1B in milestones plus tiered royalties, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Crispr is also advancing a wholly-owned pipeline of allogeneic gene edited CAR-Ts, adds the analyst. He estimates the company now holds pro forma cash of $631M and says it remains a top pick for 2019. Tenthoff boosted his price target for the shares to $100 from $75 and reiterates an Overweight rating on the name. Crispr Therapeutics in premarket trading is up 9% to $40.69.
04/30/19
PIPR
04/30/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics remains a top pick for 2019 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Crispr Therapeutics remains a top pick for 2019 following the company's Q1 results. The company has a cash position of $456M its Phase I/II study of CTX001 in transfusion-dependent beta thalassemia is "on-going," which suggests the first patient has successfully engrafted representing a "significant milestone," Tenthoff tells investors in a research note. He expects "first-in-man data" from both Phase I/II studies later this year to "serve as a major driver" and reiterates an Overweight rating on the stock with a $75 price target.
FATE Fate Therapeutics
$19.51

-0.2 (-1.01%)

06/12/19
MZHO
06/12/19
INITIATION
Target $27
MZHO
Buy
Fate Therapeutics initiated with a Buy at Mizuho
Mizuho Securities analyst Mara Goldstein started Fate Therapeutics with a Buy rating and $27 price target. The analyst sees "transformative potential" in the company's induced pluripotent stem cell derived natural killer cell therapies for the treatment of various cancers. She believes the initial data in late 2019 could bring a "wider audience" for the shares.
06/07/19
06/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sabre (SABR) initiated with a Buy at Mizuho. 2. Establishment Labs (ESTA) initiated with an Overweight at Stephens. 3. Fate Therapeutics (FATE) initiated with a Neutral at Roth Capital. 4. Select Interior Concepts (SIC) initiated with a Buy at Seaport Global. 5. Applied Materials (AMAT) initiated with a Neutral at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/19
05/30/19
INITIATION
Target $25

Buy
Rubius Therapeutics, Fate Therapeutics initiated with a Buy at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt initiated Rubius Therapeutics (RUBI) and Fate Therapeutics (FATE) with a Buy rating and Allogene Therapeutics (ALLO) with a Neutral rating as part of a broader research note of 3 biotechnology stocks that developed "innovative" next-gen cell therapy platforms. The analyst has a $25 price target on Fate Therapeutics, saying the company could "leapfrog" competitors by applying its induced pluripotent stem cell, or iPSC, platform toward "engineered off-the-shelf cancer immunotherapies in a dish". While still at an early stage, Schmidt says the platform may improve upon its initial shortcomings in first and also second generation cellular cancer immunotherapies toward a broad set of therapeutic areas. The analyst is also positive on the "unique red cell therapeutics platform" of Rubius Therapeutics and its upcoming proof-of-concept data in the second half of this year, with an "extremely broad" range of potential applications including rare genetic diseases to cancer and autoimmune diseases. Schmidt also assigns $25 price target to Rubius. For Allogene Therapeutics, Schmidt says he is positive on its potential front-runner status in bringing off-the-shelf CAR-T to market, but sees much of its potential having been priced into the stock.
06/07/19
ROTH
06/07/19
INITIATION
Target $20
ROTH
Neutral
Fate Therapeutics initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler started Fate Therapeutics with a Neutral rating and $20 price target. The analyst is are "highly optimistic" about the potential of Fate's cell therapy platform but sees "very few" share catalysts in 2019.
ARVN Arvinas
$23.38

0.93 (4.14%)

06/05/19
SBSH
06/05/19
DOWNGRADE
Target $22
SBSH
Neutral
Arvinas downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Arvinas to Neutral from Buy while raising his price target for the shares to $22 from $21. With the stock up 38% since the initial public offering, the analyst now sees a balanced risk/reward. However, he continues to like the fundamentals around Arvinas' protein degradation platform. Further, the company's new Bayer deal could have long-term upside, Nochomovitz tells investors in a research note.
06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
05/08/19
PIPR
05/08/19
NO CHANGE
Target $32
PIPR
Overweight
Arvinas price target raised to $32 from $23 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arvinas to $32 from $23 after adding value for the company's new Tau program. The analyst reiterates an Overweight rating on the shares.
04/11/19
EVER
04/11/19
INITIATION
Target $24
EVER
Outperform
Arvinas initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Arvinas with an Outperform rating and a price targets of $24. The analyst sees the company as a "leading player in protein degradation" and the only one being at the clinical stage, offering a "high potential for scalability modularity".

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

, SPX

S&P 500

$0.00

(0.00%)

20:32
07/18/19
07/18
20:32
07/18/19
20:32
General News
Trump to nominate Gene Scalia as Secretary of Labor »

President Trump tweeted:…

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$128.40

1.355 (1.07%)

, BLK

BlackRock

$474.98

4.06 (0.86%)

20:25
07/18/19
07/18
20:25
07/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AXP

American Express

$128.40

1.355 (1.07%)

BLK

BlackRock

$474.98

4.06 (0.86%)

SLB

Schlumberger

$38.78

0.15 (0.39%)

SYF

Synchrony

$36.09

0.54 (1.52%)

STT

State Street

$56.27

1.67 (3.06%)

CFG

Citizens Financial

$34.62

0.27 (0.79%)

RF

Regions Financial

$14.76

0.06 (0.41%)

KSU

Kansas City Southern

$118.03

1.22 (1.04%)

ALV

Autoliv

$69.88

0.04 (0.06%)

GNTX

Gentex

$23.54

0.01 (0.04%)

MAN

ManpowerGroup

$90.30

0.82 (0.92%)

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 06

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 27

    Oct

  • 13

    Nov

POST

Post Holdings

$108.09

0.64 (0.60%)

20:12
07/18/19
07/18
20:12
07/18/19
20:12
Upgrade
Post Holdings rating change at Piper Jaffray »

Post Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

VMW

VMware

$174.34

0.13 (0.07%)

19:01
07/18/19
07/18
19:01
07/18/19
19:01
Hot Stocks
VMware to acquire Bitfusion, terms not disclosed »

In a blog post, VMware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

, SKX

Skechers

$34.75

0.35 (1.02%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

SKX

Skechers

$34.75

0.35 (1.02%)

EXPO

Exponent

$61.63

0.83 (1.37%)

MSFT

Microsoft

$136.29

0.06 (0.04%)

CHWY

Chewy

$32.79

1.14 (3.60%)

RRGB

Red Robin

$30.58

0.32 (1.06%)

GCI

Gannett

$7.90

-0.185 (-2.29%)

IFRX

InflaRx

$3.12

0.05 (1.63%)

BA

Boeing

$361.17

-8.28 (-2.24%)

MVIS

MicroVision

$0.86

0.0458 (5.62%)

OZK

Bank OZK

$28.61

0.5 (1.78%)

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

AA

Alcoa

$23.42

0.27 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 23

    Jul

  • 24

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 26

    Aug

  • 09

    Sep

  • 23

    Sep

  • 16

    Oct

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

, MGP

MGM Growth

$30.00

-0.06 (-0.20%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Periodicals
MGM said to consider sale-leaseback of Bellagio, MGM Grand, Bloomberg says »

The report states the…

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

MGP

MGM Growth

$30.00

-0.06 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

AAL

American Airlines

$33.75

0.5 (1.50%)

, UAL

United Continental

$95.27

0.44 (0.46%)

18:49
07/18/19
07/18
18:49
07/18/19
18:49
Periodicals
POTUS meets with U.S. airlines over Qatar subsidy accusations, Reuters says »

U.S. President Donald…

AAL

American Airlines

$33.75

0.5 (1.50%)

UAL

United Continental

$95.27

0.44 (0.46%)

JBLU

JetBlue

$19.23

0.14 (0.73%)

FDX

FedEx

$165.39

0.375 (0.23%)

AAWW

Atlas Air

$42.58

0.79 (1.89%)

BA

Boeing

$361.17

-8.28 (-2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 17

    Sep

  • 13

    Nov

  • 14

    Nov

NUE

Nucor

$54.68

-0.03 (-0.05%)

18:44
07/18/19
07/18
18:44
07/18/19
18:44
Hot Stocks
Nucor CEO: We are very pleased with the results from the tariffs »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

NABZY

National Australia Bank

$0.00

(0.00%)

18:30
07/18/19
07/18
18:30
07/18/19
18:30
Hot Stocks
National Australia Bank names Ross McEwan as new CEO »

National Australia Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.48

0.3 (1.03%)

18:22
07/18/19
07/18
18:22
07/18/19
18:22
Hot Stocks
Bank of America CEO: Millennials are a huge customer base for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 06

    Sep

  • 16

    Oct

TAP

Molson Coors

$54.37

0.08 (0.15%)

18:06
07/18/19
07/18
18:06
07/18/19
18:06
Hot Stocks
Molson Coors raises quarterly dividend to 57c from 41c per share »

Molson Coors declared a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:04
07/18/19
07/18
18:04
07/18/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft up over 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

BAS

Basic Energy

$1.81

-0.1 (-5.24%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Basic Energy announces record setting lateral completion in Permian Basin »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Microsoft CFO continues to expect double digit revenue growth in FY20 »

Sees FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

QTRH

Quarterhill

$1.23

(0.00%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
WiLAN unit acquires patent portfolio from Vidiator »

Wi-LAN announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Earnings
Microsoft sees total Q1 revenue at implied $31.7B-$32.4B, consensus $32.0B »

By segment: Sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Hot Stocks
Red Robin up 17% after confirming $40.00 per share offer from Vintage Capital »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$33.09

-0.17 (-0.51%)

17:54
07/18/19
07/18
17:54
07/18/19
17:54
Periodicals
AT&T mulls sale of Puerto Rican business to pay down debt, Bloomberg says »

AT&T, which is eyeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

17:53
07/18/19
07/18
17:53
07/18/19
17:53
Hot Stocks
Red Robin confirms $40.00 per share cash buyout proposal from Vintage Capital »

Red Robin confirmed it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:50
07/18/19
07/18
17:50
07/18/19
17:50
Hot Stocks
Microsoft CFO: Q4 another quarter of double-digit top and bottom line growth »

Says commercial bookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

17:46
07/18/19
07/18
17:46
07/18/19
17:46
Hot Stocks
Harvard Bioscience names Michael Rossi CFO »

Harvard Bioscience has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:43
07/18/19
07/18
17:43
07/18/19
17:43
Hot Stocks
Microsoft CEO seeing growing momentum across every layer of its stack »

Says LinkedIn saw record…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:38
07/18/19
07/18
17:38
07/18/19
17:38
Hot Stocks
Intuitive Surgical falls after Q2 report, despite earnings beat »

Shares of Intuitive are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

GLD

SPDR Gold Shares

$136.44

1.85 (1.37%)

17:33
07/18/19
07/18
17:33
07/18/19
17:33
Hot Stocks
SPDR Gold Shares holdings rise to 814.62MT from 803.18MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$44.45

0.74 (1.69%)

17:29
07/18/19
07/18
17:29
07/18/19
17:29
Earnings
Western Alliance reports Q2 EPS 1.19, consensus $1.16 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.